Ticker >

Glenmark Life Scienc share price

Glenmark Life Sciences Ltd.

NSE: GLS BSE: 543322 SECTOR: Pharmaceuticals & Drugs  143k   831   199

791.10
-17.80 (-2.20%)
NSE: Today, 03:59 PM

Price Summary

Today's High

₹ 813.6

Today's Low

₹ 771.05

52 Week High

₹ 906

52 Week Low

₹ 411.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

9693.12 Cr.

Enterprise Value

9383.73 Cr.

No. of Shares

12.25 Cr.

P/E

18.67

P/B

3.86

Face Value

₹ 2

Div. Yield

2.65 %

Book Value (TTM)

₹  204.89

CASH

309.4 Cr.

DEBT

0 Cr.

Promoter Holding

82.85 %

EPS (TTM)

₹  42.38

Sales Growth

1.79%

ROE

22.33 %

ROCE

30.01%

Profit Growth

11.52 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year1.79%
3 Year12.02%
5 Year513.83%

Profit Growth

1 Year11.52%
3 Year14.25%
5 Year304.13%

ROE%

1 Year22.33%
3 Year37.7%
5 Year138.4%

ROCE %

1 Year30.01%
3 Year56.34%
5 Year176.47%

Debt/Equity

0

Price to Cash Flow

30.93

Interest Cover Ratio

1150.19378427788

CFO/PAT (5 Yr. Avg.)

0.861683226839623

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 82.85 9.47
Sep 2023 82.85 9.47
Jun 2023 82.85 0
Mar 2023 82.85 0
Dec 2022 82.85 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 37.7034736228694% over the past 3 years.
  • Company has been maintaining healthy ROCE of 56.3364924953257% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 1150.19378427788.
  • The Company has been maintaining an effective average operating margins of 29.6730487084973% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 87.8437808124778 days.
  • Company has a healthy liquidity position with current ratio of 2.31597859117913.

 Limitations

  • The company has shown a poor revenue growth of 12.0241695004221% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 540.73 621.32 578.45 595.36 572.8
Total Expenditure 395.28 414.89 385.29 428.28 400.25
Operating Profit 145.46 206.43 193.16 167.08 172.56
Other Income 6.61 2.84 1.85 5.37 1.69
Interest 0.16 0.12 0.4 0.4 0.39
Depreciation 10.76 11.52 12.61 13.13 13.18
Exceptional Items 0 0 0 0 0
Profit Before Tax 141.14 197.63 182 158.93 160.68
Tax 36.15 51.27 46.55 40.19 41.92
Profit After Tax 104.99 146.36 135.45 118.74 118.77
Adjusted EPS (Rs) 8.57 11.95 11.05 9.69 9.69

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 886.42 1537.31 1885.17 2123.21 2161.22
Total Expenditure 639.25 1065.35 1294.09 1507.15 1518.93
Operating Profit 247.18 471.96 591.07 616.06 642.29
Other Income 0.99 11.99 0.81 14.7 28.96
Interest 0.61 33.52 87.55 27.96 0.55
Depreciation 19.26 29.37 33.39 37.88 42.09
Exceptional Items 0 0 0 0 0
Profit Before Tax 228.3 421.07 470.94 564.93 628.61
Tax 32.71 107.97 119.36 146.2 161.65
Net Profit 195.59 313.1 351.58 418.72 466.96
Adjusted EPS (Rs.) 18.14 29.04 32.61 34.17 38.11

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 1.96 1.96 1.96 24.51 24.51
Total Reserves 86.17 399.73 750.79 2029.81 2113.7
Borrowings 0 0 0 0 0
Other N/C liabilities 6.86 16.45 22.89 32.7 59.53
Current liabilities 1380.41 1307.46 1444.93 746.8 1022.76
Total Liabilities 1475.4 1725.6 2220.57 2833.81 3220.49
Assets
Net Block 456.31 546.25 572.8 589.76 780.63
Capital WIP 80.33 10.73 14.1 91.69 49.35
Intangible WIP 0.07 0 0 5.27 12.26
Investments 0.08 0.08 0.08 0.08 0.08
Loans & Advances 7.92 8.44 11.06 19.63 9.49
Other N/C Assets 0 0 0 0 0
Current Assets 930.7 1160.11 1622.53 2127.39 2368.68
Total Assets 1475.4 1725.6 2220.57 2833.81 3220.49
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 228.3 421.07 470.94 564.93 628.61
Adjustment -101.15 56.74 133.31 70.99 35.32
Changes in Assets & Liabilities -93.26 -190.26 -107.58 99.84 -196.96
Tax Paid -23.54 -92.54 -108.56 -138.17 -153.57
Operating Cash Flow 10.35 195.01 388.11 597.59 313.4
Investing Cash Flow -8.83 -50.52 -68.73 -122.23 -154.15
Financing Cash Flow 0.54 -136.55 -213.78 -78.8 -387.59
Net Cash Flow 2.05 7.94 105.6 396.56 -228.33

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 82.85 82.85 82.85 82.85 82.85
glenmark pharmaceuticals ... 82.84 82.84 82.84 82.84 82.84
glenn mario saldanha 0.01 0.01 0.01 0.01 0.01
PARTICULARS Sep 2021% Dec 2021% Mar 2022% Jun 2022% Dec 2023%
investors 17.16 17.15 17.15 17.15 17.15
massachusetts institute o... - - - - 1.43
polar capital funds plc -... 2.46 2.46 1.99 1.32 -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Glenmark Life Sciences informs about disclosure22 Mar 2024, 12:52PM Nirma acquires majority stake in Glenmark Life Sciences13 Mar 2024, 12:09PM Glenmark Life Sciences informs about offer letter9 Feb 2024, 11:52AM Glenmark Life Scienc - Quaterly Results23 Jan 2024, 5:20PM Glenmark Life Scienc - Quaterly Results23 Jan 2024, 5:20PM Glenmark Life Sciences inks pact with Japanese innovator pharmaceutical company19 Jan 2024, 10:40AM Glenmark Life Sciences informs about media release19 Jan 2024, 10:16AM CCI gives green signal for Nirma’s acquisition in Glenmark Life Sciences20 Dec 2023, 5:23PM Glenmark Life Scienc - Quaterly Results20 Oct 2023, 1:11PM Glenmark Life Scienc - Quaterly Results20 Oct 2023, 1:11PM Glenmark Life Sciences informs about disclosure26 Sep 2023, 12:53PM Glenmark Life Sciences informs about withdrawal of voluntary issuer rating 23 Sep 2023, 10:20AM Glenmark Life Scienc - Quaterly Results21 Jul 2023, 12:55PM Glenmark Life Scienc - Quaterly Results21 Jul 2023, 12:55PM Glenmark Life Scienc - Quaterly Results21 Jul 2023, 12:55PM Glenmark Life Scienc - Quaterly Results27 Apr 2023, 5:40PM Glenmark Life Scienc - Quaterly Results27 Apr 2023, 5:40PM Glenmark Life Scienc - Quaterly Results27 Apr 2023, 5:40PM Glenmark Life Scienc - Quaterly Results27 Jan 2023, 12:55PM Glenmark Life Scienc - Quaterly Results27 Jan 2023, 12:55PM Glenmark Life Scienc - Quaterly Results27 Jan 2023, 12:55PM Glenmark Life Sciences informs about newspaper advertisement3 Dec 2022, 3:36PM Glenmark Life Sciences informs about earnings call transcript27 Oct 2022, 12:04PM Glenmark Life Sciences informs about earnings call22 Oct 2022, 4:34PM Glenmark Life Scienc - Quaterly Results21 Oct 2022, 1:30PM Glenmark Life Scienc - Quaterly Results21 Oct 2022, 1:30PM Glenmark Life Scienc - Quaterly Results21 Oct 2022, 1:30PM Glenmark Life Sciences informs about AGM30 Aug 2022, 3:54PM Glenmark Life Sciences informs about monitoring agency report12 Aug 2022, 5:12PM Glenmark Life Scienc - Quaterly Results4 Aug 2022, 6:21PM Glenmark Life Scienc - Quaterly Results4 Aug 2022, 6:21PM Glenmark Life Scienc - Quaterly Results4 Aug 2022, 6:21PM Glenmark Life Sciences informs about monitoring agency report13 May 2022, 4:27PM Glenmark Life Sciences informs about audio recordings of earnings call22 Apr 2022, 12:16PM Glenmark Life Sciences informs about outcome of board meeting21 Apr 2022, 9:51AM Glenmark Life Scienc - Quaterly Results20 Apr 2022, 7:35PM Glenmark Life Scienc - Quaterly Results20 Apr 2022, 7:35PM Glenmark Life Scienc - Quaterly Results8 Feb 2022, 6:44PM Glenmark Life Scienc - Quaterly Results8 Feb 2022, 6:44PM Glenmark Life Sciences informs about board meeting8 Nov 2021, 2:17PM Glenmark Life Sciences informs about earnings call3 Nov 2021, 3:28PM Glenmark Life Sciences coming with an IPO to raise upto Rs 1552 crore26 Jul 2021, 12:30PM Glenmark Life Sciences gets SEBI’s go-ahead to raise funds via IPO9 Jun 2021, 5:32PM

Glenmark Life Scienc Stock Price Analysis and Quick Research Report. Is Glenmark Life Scienc an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Glenmark Life Scienc and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Glenmark Life Scienc cash from the operating activity was Rs 313.404 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Glenmark Life Scienc has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Glenmark Life Scienc , the EPS growth was 11.5199592679944 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Glenmark Life Scienc has OPM of 29.7190013048186 % which is a good sign for profitability.
     
  • ROE: Glenmark Life Scienc have a healthy ROE of 22.3301416576087 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Glenmark Life Scienc is Rs 791.1. One can use valuation calculators of ticker to know if Glenmark Life Scienc share price is undervalued or overvalued.
Last Updated on:
Brief about Glenmark Life Scienc

Glenmark Life Sciences Limited Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Glenmark Life Sciences Limited is a leading player in the pharmaceutical industry. The company is engaged in the manufacturing of active pharmaceutical ingredients (APIs) and intermediates. With a focus on research and development, innovation, and quality manufacturing processes, Glenmark Life Sciences has established itself as a reliable and trusted partner in the pharmaceutical sector.

Glenmark Life Sciences Limited - Share Price

Through detailed analysis and research, our pre-built screening tools provide real-time updates on Glenmark Life Sciences Limited's share price. Investors can track and monitor the performance of the stock, enabling them to make informed decisions based on the fluctuations in market prices.

Glenmark Life Sciences Limited - Balance Sheet

The balance sheet is a key financial statement that provides a snapshot of a company's financial position. By utilizing our premium features, investors can access the tools necessary to evaluate Glenmark Life Sciences Limited's balance sheet. Our fair value calculation tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis assist investors in determining the intrinsic value of the stock.

Glenmark Life Sciences Limited - Annual Report

Annual reports play a vital role in understanding a company's financial performance and future prospects. Glenmark Life Sciences Limited's annual reports are available for download on our website. By studying these reports, investors gain valuable insights into the company's strategies, achievements, and challenges, enabling them to make well-informed investment decisions.

Glenmark Life Sciences Limited - Dividend

Dividends are an essential consideration for long-term stock investors. The company's dividend history and payout ratio are crucial factors to analyze when assessing the potential returns from investing in Glenmark Life Sciences Limited. Our platform provides comprehensive dividend information to help investors evaluate the company's dividend-paying track record.

Glenmark Life Sciences Limited - Quarterly Result

Our website provides up-to-date information on Glenmark Life Sciences Limited's quarterly results. This allows investors to stay informed about the company's financial performance throughout the year. Combined with our premium tools, investors can analyze the quarterly results and make informed decisions regarding their investments.

Glenmark Life Sciences Limited - Stock Price

The stock price of Glenmark Life Sciences Limited is influenced by various factors, including market conditions, industry performance, and company-specific developments. Our platform offers real-time stock price updates, allowing investors to monitor changes in the stock's valuation.

Glenmark Life Sciences Limited - Price Chart

Our website features comprehensive price charts for Glenmark Life Sciences Limited. These charts provide visual representations of the stock's price movements over specific periods, helping investors identify trends and patterns. By studying price charts, investors can make informed decisions based on historical price movements.

Glenmark Life Sciences Limited - News

Stay updated on the latest news and developments surrounding Glenmark Life Sciences Limited. Our platform provides a dedicated news section that covers important announcements, regulatory updates, and market trends impacting the pharmaceutical industry. Access to timely and relevant news helps investors stay informed and make sound investment decisions.

Glenmark Life Sciences Limited - Concall Transcripts

Glenmark Life Sciences Limited's con-call transcripts are available for download on our website. These transcripts provide detailed insights into management discussions, strategies, and outlooks, which can be instrumental in evaluating the company's potential as an investment.

Glenmark Life Sciences Limited - Investor Presentations

Investor presentations offer valuable information about a company's operations, growth opportunities, and financial performance. Glenmark Life Sciences Limited's investor presentations are easily accessible on our website, providing investors with comprehensive insights into the company's performance.

Glenmark Life Sciences Limited - Promoters

Promoters play a crucial role in a company's growth and success. Glenmark Life Sciences Limited's promoters have demonstrated their commitment to the company's growth and have a significant stake in its operations. By understanding the promoters' background, investors can gain confidence in the company's long-term prospects.

Glenmark Life Sciences Limited - Shareholders

The shareholder base of Glenmark Life Sciences Limited is an important aspect to consider for investors. Our platform provides comprehensive information on the company's major shareholders, enabling investors to evaluate the company's ownership structure and potential impact on decision-making.

Please note that our website offers pre-built screening tools, premium features for fair value calculation, and downloadable resources such as annual reports, con-call transcripts, investor presentations, credit ratings, and research reports for Glenmark Life Sciences Limited. These tools and resources are designed to assist long-term stock investors in conducting in-depth stock analysis and making informed investment decisions.

Read More
X